Search - tctmd.com

Displaying 481 - 500 of 3309

Sort: Relevancy | Date

Presentation THT 2025

Association of Temporary Mechanical Circulatory Support With Allosensitization and Cardiac Transplant Outcomes

Presenter: Jason Feinman

February 11, 2025

Presentation THT 2025

Association of SGLT2 Inhibitors With Clinical Outcomes in Patients With Severe Renal Impairment (Estimated Glomerular Filtration Rate < 30) and Heart Failure With Reduced Ejection Fraction (HFrEF)

Presenter: Jonathan Zawadzki

February 11, 2025

Presentation THT 2025

Winning the War on Shock: Insights From the Premier Database

Presenter: Joseph Ibrahim

February 11, 2025

Presentation THT 2025

Determining Equity and Timeliness of ATTR-CM Diagnosis

Presenter: Anubodh Varshney

February 11, 2025

Presentation THT 2025

Disparities in MDD Incidence Between HFpEF and HFrEF Patients

Presenter: Ibrahim Kamel

February 11, 2025

Presentation THT 2025

Evaluating the Impact of Sglt2 Inhibitors on Outcomes in Patients With Sarcoidosis and Heart Failure With Preserved Ejection Fraction

Presenter: Emmanuel Otabor

February 11, 2025

Presentation THT 2025

Welcome

Presenter: Daniel Burkhoff

February 11, 2025

Presentation THT 2025

Shaping the Future of Heart Failure

Presenter: Anu Lala-Trindade (Lala)

February 11, 2025

Presentation THT 2025

Obesity, Insulin Resistance, and Cardiovascular Disease: The Link between Metabolism and Inflammation

Presenter: Carolyn Lam

February 11, 2025

Presentation THT 2025

Case Discussion and Panel Q&A: Multidisciplinary Approaches to Managing Inflammation and Obesity in CVD

Presenter: Josephine Harrington

February 11, 2025

Presentation THT 2025

Mechanistic Observations of How an Atrial Shunt Impacts the Hearts of HFrEF Patients

Presenter: NULL

February 11, 2025

Presentation THT 2025

Mechanistic Observations of How an Atrial Shunt Impacts the Hearts of HFpEF Patients

Presenter: James Udelson

February 11, 2025

Presentation THT 2025

The Enduring Unmet Clinical Needs Amongst Patients Treated for Heart Failure

Presenter: Jane Wilcox

February 11, 2025

Presentation THT 2025

Inflammation and Heart Failure: Pathophysiology and Clinical Implications

Presenter: Marat Fudim

February 11, 2025

Presentation THT 2025

Emerging Therapies Targeting Inflammation and Metabolic Dysfunction in Heart Failure

Presenter: Mark Petrie

February 11, 2025

Presentation THT 2025

Cardiac Microcurrent Application for the Reversal of Heart Failure

Presenter: Eduardo Rame

February 11, 2025

Presentation THT 2025

Atrial Shunt for Heart Failure With Preserved and Mildly Reduced Ejection Fraction: Five-Year Outcomes in the REDUCE LAP-HF II Trial

Presenter: Sanjiv Shah

February 11, 2025

Presentation THT 2025

Right Ventricular to Pulmonary Artery Coupling and Clinical Outcomes After Interatrial Shunting in Heart Failure

Presenter: Stefan Anker

February 11, 2025

Presentation THT 2025

Duration of Heart Failure, Cardiac Dysfunction and Remodeling, and Response to Atrial Shunt Treatment in HFpEF and HFmrEF

Presenter: Barry Borlaug

February 11, 2025

Presentation THT 2025

Con

Presenter: Zachary Cox

February 11, 2025

Advertisement

Association of Temporary Mechanical Circulatory Support With Allosensitization and Cardiac Transplant Outcomes

Association of SGLT2 Inhibitors With Clinical Outcomes in Patients With Severe Renal Impairment (Estimated Glomerular Filtration Rate < 30) and Heart Failure With Reduced Ejection Fraction (HFrEF)

Winning the War on Shock: Insights From the Premier Database

Determining Equity and Timeliness of ATTR-CM Diagnosis

Disparities in MDD Incidence Between HFpEF and HFrEF Patients

Evaluating the Impact of Sglt2 Inhibitors on Outcomes in Patients With Sarcoidosis and Heart Failure With Preserved Ejection Fraction

Welcome

Shaping the Future of Heart Failure

Obesity, Insulin Resistance, and Cardiovascular Disease: The Link between Metabolism and Inflammation

Case Discussion and Panel Q&A: Multidisciplinary Approaches to Managing Inflammation and Obesity in CVD

Mechanistic Observations of How an Atrial Shunt Impacts the Hearts of HFrEF Patients

Mechanistic Observations of How an Atrial Shunt Impacts the Hearts of HFpEF Patients

The Enduring Unmet Clinical Needs Amongst Patients Treated for Heart Failure

Inflammation and Heart Failure: Pathophysiology and Clinical Implications

Emerging Therapies Targeting Inflammation and Metabolic Dysfunction in Heart Failure

Cardiac Microcurrent Application for the Reversal of Heart Failure

Atrial Shunt for Heart Failure With Preserved and Mildly Reduced Ejection Fraction: Five-Year Outcomes in the REDUCE LAP-HF II Trial

Right Ventricular to Pulmonary Artery Coupling and Clinical Outcomes After Interatrial Shunting in Heart Failure

Duration of Heart Failure, Cardiac Dysfunction and Remodeling, and Response to Atrial Shunt Treatment in HFpEF and HFmrEF

Con

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content